medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 2

<< Back Next >>

Med Int Mex 2011; 27 (2)

Rational perspective, and current, use of Monoamine Oxidase Inhibitors type B in treatment of Parkinson’s disease

García S, López B, Meza E, Castillo JL, Villagómez AJ, Coral VR

Language: Spanish
References: 33
Page: 168-178
PDF size: 703.43 Kb.


ABSTRACT

Background: the agitans paralysis described the early 1800S but it was not until the end of the same century when coined the eponymous of Parkinson's disease; however, there is evidence that this disease there since ancient times. Since it is still an incurable disease, from then until the date your treatment remains a challenge, despite the therapeutic resources now available.
Objective: to realize a short historical review about Parkinson’s disease treatments and update analysis about Monoamine Oxidase Inhibitors type B in Parkinson’s disease management.
Material y Methods: We made a bibliographic search by internet into Goglee, Pubmed and Ovid using following key words: Parkinson’s disease, Parkinson’s disease options of managements, Monoamine Oxidase Inhibitors type B in Parkinson’s disease, selegiline & rasagiline and Parkinson’s disease. We got more of 90,000 papers, form them we chose just complete historical treatment compilation and medical articles with evidence label I or Meta analysis. At end 33 papers were chosen.
Conclusions: We made different treatments synopsis used for Parkinson´s disease, the beginning of levodopa use and Monoamine Oxidase Inhibitors type B in Parkinson’s disease update management.


REFERENCES

  1. History, Progress, and Current treatment of Parkinson’s disease. 1817-2002. Disponible en: http://www.rafink.com/ downloads/parktalk.doc

  2. Historia: La enfermedad. Asociación Parkinson Madrid. Disponible en: http://www.parkinsonmadrid.org/historia.asp

  3. Mulheam RJ. The shaking palsy. The history of Dr. James Parkinson. Disponible en: http://www.parkinsons.ca/Week12.htm

  4. Parkinson’s disease. Disponible en: http://sulcus. berkeley. edu/mcb /165_001/papers/man

  5. Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease. Neurology 1996;46:92-230.

  6. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-458.

  7. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol 1996;39(1):29-36.

  8. Maruyama W, Akao Y, Carrillo MC, Kitani K, et al. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24:675-682.

  9. A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-248.

  10. Shingo T, Date I, Yoshida H, Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson’s disease. J Neurosci Res 2002;69:946-954.

  11. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-Binhibitor for the treatment of Parkinson’s disease: a double-blind study asadjunctive therapy to levodopa. Clin Neuropharmacol 2000;23:324-330.

  12. Rascol O, Brooks DJ, Melamed E, et al. A comparative randomized study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson’s disease (PD) patients with motor fluctuations (the LARGO Study).On behalf of the LARGO Study Group. Eur J Neurol 2003;10:234-244.

  13. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.

  14. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors inearly Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.

  15. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of (-) deprenyl to Madopar treatment in Parkinson’s disease: A long term study. Journal of Neural Transmission 1985;64(2):113-127.

  16. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine- analog synthesis. Science 1983;219:979-980.

  17. Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996;47(6 suppl 3):S210-S216.

  18. Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease. Neurology 2006;66(10 suppl 4):S69-S79.

  19. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-515.

  20. Carlile GW, Chalmers-Redman RME, Tatton NA, Borden KLB. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehydes-3-phosphate dehydrogenase to a dimer. Mol Pharm 2000;57:2-12.

  21. Hara MR, Thomas B, Cascio MB, Fujimuro M, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 2006;103:3887-3889.

  22. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176-183.

  23. Olanow CW, Hauser RA, Gauger L, Malapira T, et al. The effect of deprenyl and levodopa on the progression of Parkinson’sdisease. Ann Neurol 1995;38:771-777.

  24. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C; Parkinson Study Grou. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56:1712-1721.

  25. Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Ma¨ki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-1206.

  26. Olanow CW, Hauser R, Jankovic J, et al. A randomized,doubleblind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (The ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194-2201.

  27. Schapira AHV, Olanow CW. Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions. JAMA 2004;291(3):358-364 (doi:10.1001/jama.291.3.358).

  28. Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Inhibidores de monoaminooxidasa B versus otros agentes dopaminérgicos en la enfermedad de Parkinson temprana In: Biblioteca Cochrane Plus 2009 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com

  29. Calne DB. Selegiline in Parkinson’s disease. BMJ 1995;311(7020):1583-1584.

  30. Lees AJ, Abbott R, Banerji N, Barrie M, et al. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311(7020):1602-1607

  31. Breteler MM. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be. BMJ 1998;316(7139):1182-1183.

  32. Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson’s disease. Cochrane Database of Systematic Reviews 2005, Issue 3. [Art. No.: CD004898. DOI: 10.1002/14651858.CD004898.pub2]

  33. 29 Schapira AHV. Present and future drug treatment for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:1472-1478. doi: 10.1136/jnnp.2004.035980




2020     |     www.medigraphic.com